Infectious Disease Research Institute donations received

This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of December 2019. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.

Table of contents

Basic donee information

ItemValue
Country
Websitehttp://www.idri.org
Twitter usernameIDRItweets
Wikipedia pagehttps://en.wikipedia.org/wiki/Infectious_Disease_Research_Institute

Donee donation statistics

Cause areaCountMedianMeanMinimum10th percentile 20th percentile 30th percentile 40th percentile 50th percentile 60th percentile 70th percentile 80th percentile 90th percentile Maximum
Overall 19 942,789 5,141,714 -2,590,788 500 500,000 680,000 773,722 942,789 3,386,540 3,837,627 7,031,776 29,947,850 32,056,244
Global health 18 942,789 5,427,337 -2,590,788 100,000 602,654 724,636 833,750 942,789 3,386,540 3,837,627 7,031,776 29,947,850 32,056,244
Sectors not specified 1 500 500 500 500 500 500 500 500 500 500 500 500 500

Donation amounts by donor and year for donee Infectious Disease Research Institute

Donor Total 2018 2017 2016 2015 2014 2013 2012 2011 2010 2008 2007 2006
Bill and Melinda Gates Foundation (filter this donee) 97,692,570.00 4,337,627.00 602,654.00 -1,757,038.00 6,226,952.00 943,289.00 4,111,176.00 9,778,596.00 680,000.00 3,733,444.00 7,031,776.00 29,947,850.00 32,056,244.00
Total 97,692,570.00 4,337,627.00 602,654.00 -1,757,038.00 6,226,952.00 943,289.00 4,111,176.00 9,778,596.00 680,000.00 3,733,444.00 7,031,776.00 29,947,850.00 32,056,244.00

Full list of donations in reverse chronological order (19 donations)

DonorAmount (current USD)Amount rank (out of 19)Donation dateCause areaURLInfluencerNotes
Bill and Melinda Gates Foundation500,000.00162018-10-26Global health/Health policy and administrative managementhttps://iatiregistry.org/publisher/bmgf-- to provide Good Manufacturing Practices material for human clinical trials and maintain clinical readiness of the facility and compliance with Food and Drug Administration regulations; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation3,837,627.0062018-01-25Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to identify new leads and new drug targets for tuberculosis suitable for further drug development with the ultimate goal of producing new drugs to treat tuberculosis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation602,654.00152017-11-06Global health/basic health carehttps://iatiregistry.org/publisher/bmgf-- to provide foundation grantees with novel and innovative industry quality adjuvants and formulations to enhance the success of pre-clinical and clinical vaccine development; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation833,750.00112016-08-26Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to identify new leads and new drug targets for tuberculosis suitable for further drug development with the ultimate goal of producing new drugs to treat tuberculosis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation-2,590,788.00192016-05-19Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to eliminate leishmaniasis by developing a vaccine for use in both treatment and prevention; Aid type: Project-type interventions. Affected regions: South America|Africa; affected countries: India|Bangladesh.
Bill and Melinda Gates Foundation4,349,073.0052015-10-06Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to enhance IDRI’s capabilities to provide industry quality adjuvants and formulations for the development of vaccines for diseases in the developing world; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation773,722.00122015-10-05Global health/basic health carehttps://iatiregistry.org/publisher/bmgf-- to provide foundation grantees with novel and innovative industry quality adjuvants and formulations to enhance the success of pre-clinical and clinical vaccine development; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation1,004,157.0092015-09-11Global health/Health policy and administrative managementhttps://iatiregistry.org/publisher/bmgf-- to provide Good Manufacturing Practices material for human clinical trials and maintain clinical readiness of the facility and compliance with Food and Drug Administration regulations; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation100,000.00172015-04-17Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to provide support to launch Global Health Vaccine Accelerator Platform (GH-VAP) for the adjuvants and formulations platform; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation942,789.00102014-11-04Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to identify new leads and new drug targets for tuberculosis suitable for further drug development with the ultimate goal of producing new drugs to treat tuberculosis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation500.00182014-09-22Sectors not specifiedhttps://iatiregistry.org/publisher/bmgf-- to support the Starting Gates partnership. Starting Gates 8/12/14. Investment start date: 9/22/2014 to end date: 9/26/2014. Grantee name: Infectious Disease Research Institute; Aid type: Project-type interventions. Affected countries: United states of america (the).
Bill and Melinda Gates Foundation3,386,540.0082013-10-30Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to identify new leads and new drug targets for tuberculosis suitable for further drug development with the ultimate goal of producing new drugs to treat tuberculosis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation724,636.00132013-10-24Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop a research tool to identify individuals infected with Leishmania donovani parasites in the absence of visceral leishmaniasis disease to better understand their role in transmission.; Aid type: Project-type interventions. Affected regions: South of Sahara|South America; affected countries: India|Bangladesh.
Bill and Melinda Gates Foundation9,778,596.0032012-11-06Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop and provide access to industry quality adjuvants and formulations to foundation grantees/collaborators and to bring forward one lead vaccine candidate for a foundation high priority disease.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation680,000.00142011-11-07Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to identify new leads and new drug targets for tuberculosis suitable for further drug development with the ultimate goal of producing new drugs to treat tuberculosis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation3,733,444.0072010-11-18Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to identify new leads and new drug targets for tuberculosis suitable for further drug development with the ultimate goal of producing new drugs to treat tuberculosis; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation7,031,776.0042008-10-28Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop a highly specific diagnostic test and an accurate test of cure for visceral leishmaniasis; Aid type: Project-type interventions. Affected regions: Africa.
Bill and Melinda Gates Foundation29,947,850.0022007-11-01Global health/malariahttps://iatiregistry.org/publisher/bmgf-- to provide adjuvants for priority vaccine candidates with emphasis on malaria. Adjuvant to Enable New Vaccines Product Development Partnership. Investment start date: 10/14/2007 to end date: 6/30/2014. Grantee name: Infectious Disease Research Institute; Aid type: Project-type interventions. Affected regions: South of Sahara.
Bill and Melinda Gates Foundation32,056,244.0012006-08-07Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to eliminate leishmaniasis by developing a vaccine for use in both treatment and prevention; Aid type: Project-type interventions. Affected regions: South America|Africa; affected countries: India|Bangladesh.